Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review

Migliorini, Filippo; Maffulli, Nicola; Spiezia, Filippo; Tingart, Markus; Maria, Peretti Giuseppe; Riccardo, Giorgino

doi:10.1186/s13018-021-02474-7

Journal of Orthopaedic Surgery and Research

Table 1 Generalities and patient baseline data of the included studies

From: Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review

Author, year	Journal	Mean follow-up (*months*)	Mean calcium daily supplement (mg)	Mean vit D daily supplement (UI)	Treatment	Administration	Samples (n)	Mean age	Mean BMI (*kg/m2*)	Mean BMD Spine (*g/cm*²)	Mean BMD Hip (*g/cm2*)	Mean BMD Femur neck (*g/cm*²)
Bone et al., 1997 [18]	J Clin Endocrinol Metab	24	813		Alendronate	OS	86	71
			880		Alendronate	OS	89	70
			831		Alendronate	OS	93	71
			900		Placebo	OS	91	71
Brown et al., 2014 [31]	Osteoporos Int	12			Denosumab	SC	852	68
					Ibandronate	OS	851	67
					Risedronate	OS	851	67
Chung et al., 2009 [32]	Calcif Tissue Int	6	500	125	Ibandronate/Risedronate	OS	176	61	23.30
				125	Risedronate/Ibandronate	OS	176	62	23.40
					Placebo	OS	44	70	25.10	0.75		0.61
Delmas et al., 2002 [33]	J Clin Endocrinol Metab	48	500	400-600	Raloxifene	OS	2259	66	25.30	0.82		0.62
					Raloxifene	OS	2277	66	25.20	0.81		0.62
					Placebo	OS	2292	67	25.30	0.81		0.62
Gonnelli et al., 2014 [34]	Bone	12	841	400	Zoledronate	IV	30	66	26.10	0.82	0.79
Gonnelli et al., 2014 [34]		12	870		Ibandronate	IV	30	67	25.70	0.82	0.79
Grey et al., 2012 [35]	J Clin Endocrinol Metab	12	960		Zoledronate	IV	43	64		1.01	0.85
			880		Zoledronate	IV	43	66		1.03	0.84
			850		Zoledronate	IV	43	66		1.05	0.84
			950		Placebo	IV	43	65		1.03	0.87
Harris et al., 1999 [19]	JAMA	36	1000	500	Risedronate	OS	817	69	26.60	0.84		0.60
					Risedronate	OS	821	69	26.60	0.83		0.59
					Placebo	OS	820	68	26.50	0.83		0.60
Hooper et al., 2005 [36]	Climacteric	24			Risedronate	1OS	128	53		1.08
					Risedronate	OS	129	53		1.08
					Placebo	OD	126	53		1.08
Iwamoto et al., 2008 [37]	Yonsei Med J	12	800		Alendronate	OS	61	70	21.90	0.62
Iwamoto et al., 2008 [37]	Yonsei Med J	12	800		ECT	OS	61	69	21.70	0.65
Iwamoto et al., 2011 [38]	Osteoporosis Int	6	800		Alendronate	OS	97	78	22.00
Iwamoto et al., 2011 [38]	Osteoporosis Int	6	800		Raloxifene	IM	97	82	21.90
Leder et al., 2014 [39]	J Clin Endocrinol Metab	24			Teriparatide	SC	31	66	25.50	0.82		0.64
					Denosumab	SC	33	66	24.10	0.87		0.64
					Combined	SC	30	66	25.40	0.86		0.64
Liang et al., 2017 [40]	Orthop Surg	24			Zoledronate	IV	155	57	21.80	0.63	0.75
Liang et al., 2017 [40]	Orthop Surg	24			Placebo	IV	95	57	21.60	0.63	0.75
Lufkin et al., 1998 [41]	J Bone Min Res	12			Raloxifene	OS	48	67	24.80	0.75	0.64
					Raloxifene	OS	47	67	26.20	0.81	0.69
			750	400	Calcium/Vit D	OS	48	68	25.30	0.77	0.67
Muratore et al., 2010 [42]	Adv Ther	12	1000	800	Clodronate	IM	28	64
Muratore et al., 2010 [42]	Adv Ther	12	1000	800	Clodronate	IM	32	64
Paggiosi et al., 2014 [43]	Osteoporos Int	24	1200	800	Alendronate	OS	57	68	25.90	0.79	0.75	0.64
					Ibandronate	OS	58	67	26.40	0.80	0.78	0.64
					Risedronate	OS	57	67	26.80	0.81	0.80	0.67
					Control		226	38	25.10	1.,07	0.97	0.86
Roux et al., 2014 [44]	Bone	12	≥1000	≥800	Denosumab	SC	435	68
Roux et al., 2014 [44]	Bone	12	≥1000	≥800	Risedronate	OS	435	68

Back to article page

ISSN: 1749-799X

Contact us

Submission enquiries: journalsubmissions@springernature.com